菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

ADC Assay Services

Biology-Driven ADC Testing Services from Assay Design to Translational Insights

WuXi Biologics offers a full suite of ADC in vitro assays services to support ADC discovery, covering ADC and bispecific ADC binding characterization, antibody internalization assays, bystander killing, cytotoxicity, and serum/plasma stability analysis to help teams evaluate MOA, differentiate ADC candidates more effectively from existing therapies, and strengthen prediction of in vivo performance.

Discuss Your ADC Bioassay Projects

Fill out a short form to connect with our experts

 

Core Strength

ADC Assay Service Highlights

Build Rational Assay Strategies

Design in vitro models and select the right cell lines to differentiate ADC candidates

Support Therapeutic Window Evaluation

Apply core assays to define and optimize ADC potency and safety margins

Generate Actionable, Translational Insights

Use advanced analytical tools to turn assay data into preclinical decisions


  • Build Rational Assay Strategies Design in vitro models and select the right cell lines to differentiate ADC candidates
  • Support Therapeutic Window Evaluation Apply core assays to define and optimize ADC potency and safety margins
  • Generate Actionable, Translational Insights Use advanced analytical tools to turn assay data into preclinical decisions

Service Details

ADC In Vitro Assay Service Details

Service Item Methods Turnaround
Binding Assays
  • Protein-based (ELISA)
  • Cell-based (FACS)
1–2 weeks
ADC Cytotoxicity Assays
  • CTG, MTT, WST
2–3 weeks
Bystander Killing Assays
  • Luciferase-based cytotoxicity
2–3 weeks
Internalization Assays
  • pHrodo (Operetta)
  • Acid quench (FACS)
  • Colocalization (Operetta)
  • Time-course imaging (Incucyte)
2–3 weeks
Early Developability Evaluation
  • Serum/plasma stability (Human/cyno/mouse, ELISA/FACS)
3–4 weeks

Case Studies

Case Studies: In Vitro Assays for ADC Discovery with Translational Insights

Case Study 1: Operetta-Based Antibody Internalization Assay for Herceptin ADC Characterization

This case study highlights an Operetta-based ADC internalization assay in SK-BR-3 cells using a low-pH-dependent fluorescent readout. Herceptin ADC showed clear dose-dependent internalization, while the control showed minimal signal, supporting quantitative assessment of ADC internalization activity.

Figure showing an antibody internalization assay in SK-BR-3 cells, including a schematic of antigen binding and lysosomal trafficking, Operetta-based analysis panels for nucleus, cytoplasm, internalization, and merged views, plus a dose-response curve and summary table showing Herceptin ADC internalization with EC50 of 1.6 nM.

  • Operetta-based ADC internalization assay in SK-BR-3 cells using a low-pH-dependent fluorescent readout
  • Clear dose-dependent internalization of Herceptin ADC versus minimal signal from control
  • Quantitative assessment of ADC internalization activity with EC50 of 1.6 nM
Case Study 2: hFab-MMAE ADC Cytotoxicity Assay Supports ADC Differentiation
+

This case study highlights an hFab-MMAE ADC cytotoxicity assay used for functional comparison of different ADC leads. Following target binding and internalization, the Ab1/hFab-MMAE complex demonstrated stronger dose-dependent cytotoxicity than Ab2 and Ab3 (hFab-MMAE figure), consistent with the results observed after conjugation (ADC Cytotoxicity figure). The data suggest that the internalization behavior remained consistent before and after conjugation. This approach enables efficient differentiation of ADC leads even prior to payload conjugation.​

Case study: hFab-MMAE ADC cytotoxicity assay supporting ADC candidate differentiation through dose-dependent cytotoxicity comparison across Ab1, Ab2, and Ab3 conjugates.

  • hFab-MMAE ADC cytotoxicity assay for functional comparison of ADC candidates
  • Ab1-derived conjugates showed stronger dose-dependent cytotoxicity than Ab2 and Ab3
  • Consistent internalization pattern prior to conjugation enabling efficient ADC candidate differentiation

Why WuXi Biologics

Why Work with WuXi Biologics for ADC Assays

  • Biology-Driven Assay Design: Build fit-for-purpose ADC in vitro assays aligned with target biology, MOA, and modality
  • Core ADC Assay Coverage: Access binding, internalization, cytotoxicity, bystander killing, and serum/plasma stability assays in one place
  • Advanced Analytical Support: Generate robust, quantitative data via high-content imaging, flow cytometry, IncuCyte, and other tools
  • Better Candidate Differentiation: Use data-driven bioassays to compare ADC candidates and support in vivo prediction

Get Started

 

Move from ADC Bioassay Data to Better Translational Decisions

Advance your ADC discovery projects with WuXi Biologics’ biology-driven ADC assay platform designed to generate actionable in vitro data for lead selection and optimization. Covering binding, internalization, cytotoxicity, bystander killing, and stability assessment, we help translate assay results into clearer candidate differentiation and more confident preclinical decisions.

Talk to Our ADC In Vitro Assay Experts

 

Speak with our experts